203 related articles for article (PubMed ID: 36996387)
1. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood
van Weelderen RE; Klein K; Harrison CJ; Jiang Y; Abrahamsson J; Arad-Cohen N; Bart-Delabesse E; Buldini B; De Moerloose B; Dworzak MN; Elitzur S; Fernández Navarro JM; Gerbing RB; Goemans BF; de Groot-Kruseman HA; Guest E; Ha SY; Hasle H; Kelaidi C; Lapillonne H; Leverger G; Locatelli F; Masetti R; Miyamura T; Norén-Nyström U; Polychronopoulou S; Rasche M; Rubnitz JE; Stary J; Tierens A; Tomizawa D; Zwaan CM; Kaspers GJL
J Clin Oncol; 2023 Jun; 41(16):2963-2974. PubMed ID: 36996387
[TBL] [Abstract][Full Text] [Related]
2. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring
Jiang B; Zhao Y; Luo Y; Yu J; Chen Y; Ye B; Fu H; Lai X; Liu L; Ye Y; Zheng W; Sun J; He J; Zhao Y; Wei G; Cai Z; Huang H; Shi J
Cell Transplant; 2024; 33():9636897231225821. PubMed ID: 38270130
[No Abstract] [Full Text] [Related]
4. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
8. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
9. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.
Huo Y; Guan XM; Dou Y; Wen XH; Guo YX; Shen YL; An XZ; Yu J
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Nov; 23(11):1111-1118. PubMed ID: 34753542
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.
Bai L; Zhang YZ; Yan CH; Wang Y; Xu LP; Zhang XH; Zhang LP; Huang XJ; Cheng YF
BMC Cancer; 2022 Aug; 22(1):896. PubMed ID: 35974319
[TBL] [Abstract][Full Text] [Related]
14. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
15. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.
Yu S; Lin T; Nie D; Zhang Y; Sun Z; Zhang Q; Wang C; Xiong M; Fan Z; Huang F; Xu N; Liu H; Yu G; Zhang H; Shi P; Xu J; Xuan L; Guo Z; Wu M; Han L; Xiong Y; Sun J; Wang Y; Liu Q
Blood Cancer J; 2021 Dec; 11(12):195. PubMed ID: 34873148
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Cheng YF; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
Ann Hematol; 2021 May; 100(5):1267-1281. PubMed ID: 33712867
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
18. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
19. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
[TBL] [Abstract][Full Text] [Related]
20. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
